Meanwhile, the group’s outlook is upbeat, with expected growth of between 3% and 5% next year in sales, and of between 7% and 9% in core operating profit. At the same time, GSK reiterated its 2031 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results